Advertisement
MTD vs TMO
Which Stock Would AI Choose? Mettler-Toledo International Inc. (MTD) vs. Thermo Fisher Scientific Inc. (TMO) Stock Comparison
Key Takeaways
- MTD has delivered stronger one-year returns of approximately 14% compared to TMO's 10%, reflecting better relative performance in recent market activity.
- TMO, with a market cap exceeding $172 billion, offers greater scale and diversification across life sciences solutions, analytical instruments, and biopharma services.
- Recent earnings show resilience: TMO reported Q1 2026 revenue growth of 6.2%, while MTD's prior quarter sales rose 8%.
- Both stocks trade at premium valuations, with P/E ratios (price-to-earnings ratios) around 30 for MTD and 25 for TMO, amid life sciences sector volatility.
- Sentiment around MTD remains mixed ahead of Q1 earnings, while TMO faces subdued outlook post-earnings despite beats.
- Investor focus on precision instruments and lab tools positions both for potential recovery in research and industrial demand.
Introduction
Mettler-Toledo International Inc. (MTD) and Thermo Fisher Scientific Inc. (TMO) are leading providers of precision instruments and services critical to life sciences, pharmaceuticals, and industrial applications. This stock comparison analyzes their recent performance, business dynamics, and market positioning amid evolving sector trends. Traders seeking momentum plays and long-term investors eyeing stability in the diagnostics and research tools space will find value in understanding their contrasts, including scale differences and growth trajectories in a volatile healthcare market.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. (MTD) specializes in precision instruments for laboratory, industrial, and retail weighing applications, serving pharmaceuticals, biotech, food, and chemical sectors worldwide. With a market capitalization of about $25 billion, the company maintains high profitability, boasting a 21.6% profit margin and return on assets near 20%. In recent market activity, MTD stock has traded around $1,260, down from its 52-week high of $1,525 but up year-to-date by nearly 10% and 14% over the past year. Sentiment reflects caution due to stagnant revenue growth concerns, though prior-quarter sales rose 8% and EPS beat expectations. Upcoming Q1 2026 earnings are anticipated with a projected 6% EPS increase, influencing price behavior amid broader life sciences recovery signals.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is a diversified giant in life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services, with operations spanning reagents, consumables, and clinical research. Its $172 billion market cap underscores its scale, supported by a 15% profit margin and robust $45 billion trailing revenue. Recently, shares hover near $465, well off the 52-week high of $644 but up about 20% year-to-date and 10% over the past year. Q1 2026 results showed 6.2% revenue growth to $11 billion and adjusted EPS of $5.44 beating estimates, driven by international strength; however, a subdued outlook led to post-earnings declines. Strategic moves like selling its microbiology unit for $1 billion have shaped sentiment in recent weeks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 AI trading bots out of 351 total, curated for superior performance in current market conditions across sectors like semiconductors, energy, and small caps. These bots deliver real-time signals for copy trading, boasting annualized returns from +23% to +162%, win rates of 51% to 88%, and profit factors up to 11.7. Trading 3 to 18 tickers each via diverse strategies—such as trend-following with take-profit/stop-loss corridors—these tools adapt to short (1-day) to longer (49-day) timeframes. Explore Tickeron’s hundreds of AI bots trading thousands of tickers to identify strategies aligning with your risk profile and market outlook.
Head-to-Head Comparison
Both MTD and TMO thrive in precision instruments for life sciences, but TMO’s broader model spans four segments for diversified revenue, contrasting MTD’s focused lab and industrial weighing emphasis. Growth drivers differ: TMO benefits from biopharma services and international expansion, while MTD leverages high-margin analytics tools. Recent momentum favors MTD on a one-year basis, though TMO leads year-to-date. Risk profiles highlight MTD’s higher beta (1.31) versus TMO’s 0.88, with sector exposures tied to research funding and industrial demand. Market sentiment tilts toward TMO for stability amid MTD’s earnings uncertainty.
Tickeron AI Verdict
Tickeron’s AI currently favors MTD over TMO, based on stronger one-year trend consistency, higher relative returns, and positive catalysts ahead of earnings in a recovering life sciences environment. While TMO offers scale advantages, MTD’s positioning suggests higher probability of near-term outperformance, subject to market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MTD is a Hold and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MTD’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- MTD’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MTD’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- MTD’s TA Score: 4 bullish, 6 bearish.
- TMO’s TA Score: 3 bullish, 7 bearish.
Price Growth
MTD (@Medical Specialties) experienced а -2.22% price change this week, while TMO (@Medical Specialties) price change was -4.00% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
Reported Earning Dates
MTD is expected to report earnings on Jul 23, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MTD | TMO | MTD / TMO | |
| Capitalization | 23.3B | 176B | 13% |
| EBITDA | 1.25B | 11.7B | 11% |
| Gain YTD | -17.204 | -18.325 | 94% |
| P/E Ratio | 27.12 | 25.99 | 104% |
| Revenue | 4.09B | 45.2B | 9% |
| Total Cash | 60.6M | 3.26B | 2% |
| Total Debt | 2.23B | 43.2B | 5% |
MTD | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 94 | |
SMR RATING 1..100 | 2 | 62 | |
PRICE GROWTH RATING 1..100 | 62 | 57 | |
P/E GROWTH RATING 1..100 | 59 | 40 | |
SEASONALITY SCORE 1..100 | 50 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is significantly better than the same rating for MTD (99). This means that TMO’s stock grew significantly faster than MTD’s over the last 12 months.
TMO's Profit vs Risk Rating (94) in the Medical Specialties industry is in the same range as MTD (100). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is somewhat better than the same rating for TMO (62). This means that MTD’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Price Growth Rating (57) in the Medical Specialties industry is in the same range as MTD (62). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
TMO's P/E Growth Rating (40) in the Medical Specialties industry is in the same range as MTD (59). This means that TMO’s stock grew similarly to MTD’s over the last 12 months.
| MTD | TMO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 63% | 3 days ago 47% |
| Stochastic ODDS (%) | 3 days ago 63% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 68% | 3 days ago 62% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 68% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 66% | 3 days ago 62% |
| Advances ODDS (%) | 7 days ago 61% | 7 days ago 62% |
| Declines ODDS (%) | 5 days ago 65% | 5 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 67% | 3 days ago 52% |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 60% |
Advertisement
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -2.22% | ||
| A - MTD | 71% Closely correlated | -2.12% | ||
| TMO - MTD | 67% Closely correlated | -1.91% | ||
| BRKR - MTD | 67% Closely correlated | -5.97% | ||
| DHR - MTD | 63% Loosely correlated | -1.25% | ||
| AZTA - MTD | 61% Loosely correlated | -0.66% | ||
More | ||||